How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

9,399 results for

Cholesterol Education Resources

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

281. Evaluation of Patients Treated With HMG-CoA Reductase Inhibitors to Reach Cholesterol Target Values

: Cohort Time Perspective: Cross-Sectional Official Title: Non-interventional Study to Assess Reaching of Cholesterol Target Values in Patients Treated With HMG-CoA Reductase Inhibitors in Bosnia and Herzegovina Study Start Date : April 2012 Actual Primary Completion Date : January 2013 Actual Study Completion Date : January 2013 Resource links provided by the National Library of Medicine related topics: Groups and Cohorts Go to Group/Cohort Patients with hypercholesterolaemia Outcome Measures Go (...) Evaluation of Patients Treated With HMG-CoA Reductase Inhibitors to Reach Cholesterol Target Values Evaluation of Patients Treated With HMG-CoA Reductase Inhibitors to Reach Cholesterol Target Values - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please

2011 Clinical Trials

282. A Study of the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients With Familial Hypercholesterolemia and Inadequately Controlled Low-Density Lipoprotein Cholesterol

, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Followed by an Open-Label Continuation Period to Assess the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients With Familial Hypercholesterolemia and Inadequately Controlled Low-Density Lipoprotein Cholesterol Actual Study Start Date : December 2011 Actual Primary Completion Date : December 29, 2015 Actual Study Completion Date : December 29, 2015 Resource links provided by the National Library of Medicine related (...) (5.18 mmol/L)) On stable, maximally tolerated, statin therapy for at least 12 weeks or if statin intolerant, on at least 1 medication from another class of hypolipidemic agents (i.e., bile acid sequestrants, niacin/nicotinic acid, cholesterol absorption inhibitors, fibrates). On stable, low fat diet for 12 weeks Body mass index (BMI) ≤40 kg/m2 and stable weight for > 6 weeks Exclusion Criteria: Significant health problems in the recent past including heart attack, stroke, coronary syndrome, unstable

2011 Clinical Trials

283. Study of Cholesterol Levels and Types in African Americans With Type 2 Diabetes

Study of Cholesterol Levels and Types in African Americans With Type 2 Diabetes Study of Cholesterol Levels and Types in African Americans With Type 2 Diabetes - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more (...) . Study of Cholesterol Levels and Types in African Americans With Type 2 Diabetes (LAAD) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01494298 Recruitment Status : Completed First Posted : December 16, 2011 Results First Posted : December 13, 2013 Last Update Posted : December 13, 2013 Sponsor

2011 Clinical Trials

284. A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/20 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 20 mg Tablets in Participants With High Cholesterol (MK-0653C-185 AM1)

Cholesterol Education Program adult treatment panel III [NCEP ATP III] guidelines) and either statin-naïve with LDL-C ≥130 mg/dL for low risk or ≥100 mg/dL for moderate or moderately high risk OR on an allowable statin with on-therapy LDL-C ≥100 mg/dL in acceptable range and can safely discontinue and switch to study medication. Is willing to maintain a cholesterol-lowering diet throughout the study. Female of reproductive potential agrees to remain abstinent or to use (or have their partner use) 2 (...) of ezetimibe + simvastatin (10/80 mg), ezetimibe + atorvastatin (10/40 mg or 10/80 mg), ezetimibe + rosuvastatin (10/10 mg, 10/20 mg, or 10/40 mg), ezetimibe + pitavastatin (10/4 mg); non-statin lipid-lowering agents including fish oils containing >900 mg/day of eicosapentaenoic acid and docosahexaenoic acid (EPA+DHA), red yeast extract, Cholestin™, bile acid sequestrants, other cholesterol-lowering agents, niacin (>200 mg/day), or fibrates; systemic corticosteroids; psyllium, other fiber-based laxatives

2011 Clinical Trials

285. A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/40 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 40 mg Tablets in Participants With High Cholesterol (MK-0653C-190 AM1)

members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years to 79 Years (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion criteria: At low, moderate, or moderately high cardiovascular risk (according to National Cholesterol Education Program (...) including fish oils containing >900 mg/day of eicosapentaenoic acid and docosahexaenoic acid (EPA+DHA), red yeast extract, Cholestin™, bile acid sequestrants, other cholesterol-lowering agents, niacin (>200 mg/day), or fibrates; systemic corticosteroids; psyllium, other fiber-based laxatives, phytosterol margarines, and/or over the counter (OTC) therapies known to affect serum lipid levels; orlistat or other anti-obesity medications and not maintained on a stable dose; any cyclical hormones; warfarin

2011 Clinical Trials

286. Anti-inflammatory Agents and Cholesterol Metabolism

of variations in degree of pro-atherogenic response of the Cholesterol Metabolic Signature to COX inhibition within human patients that may be associated with a higher likelihood of developing CV sequelae. Understanding the nature of the association between COX inhibition and cholesterol metabolism, and the extent to which they may promote atherosclerotic CV disease, is of critical importance in developing analgesic and anti-inflammatory medications with a more favorable risk profile. The knowledge gained (...) Anti-inflammatory Agents and Cholesterol Metabolism Anti-inflammatory Agents and Cholesterol Metabolism - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Anti-inflammatory Agents and Cholesterol Metabolism

2011 Clinical Trials

287. Cholesterol-lowering Effects of Lupin Protein

, 16 and 20 weeks ] Blood lipids (LDL cholesterol, total cholesterol, HDL cholesterol, triacylglyceroles) Secondary Outcome Measures : Protein metabolism [ Time Frame: After 0, 8, 12 and 20 weeks ] Plasma: amino acids, total protein, albumin, urea, uric acid; Urine: total protein, ammonia, urea, uric acid; Proteomic-study Body composition (body status) [ Time Frame: After 0, 8, 12 and 20 weeks ] Bioelectrical impedance analysis, body weight, blood pressure High-sensitive CRP [ Time Frame: After 0 (...) of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01304992 Locations Layout table for location information Germany Friedrich Schiller University Jena, Department of Nutritional Physiology Jena, Thuringia, Germany, 07743 Sponsors and Collaborators University of Jena German Federal Ministry of Education and Research

2011 Clinical Trials

288. Safety, Immunogenicity and Dose Response of ATH03, a New Vaccine Against the Cholesterol Ester Transfer Protein (CETP)

Official Title: Safety, Immunogenicity and Dose Response of ATH03, a New Vaccine Against the Cholesterol Ester Transfer Protein (CETP), in Healthy Male Subjects With High Density Lipoprotein Cholesterol (HDLc) Blood Concentrations Equal or Below 80 mg/dl Study Start Date : May 2011 Actual Primary Completion Date : July 2012 Actual Study Completion Date : July 2012 Resource links provided by the National Library of Medicine related topics: Arms and Interventions Go to Arm Intervention/treatment (...) Safety, Immunogenicity and Dose Response of ATH03, a New Vaccine Against the Cholesterol Ester Transfer Protein (CETP) Safety, Immunogenicity and Dose Response of ATH03, a New Vaccine Against the Cholesterol Ester Transfer Protein (CETP) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum

2011 Clinical Trials

289. Evaluation of Alirocumab (SAR236553/REGN727) When Co-administered With Atorvastatin in Patients With Primary Hypercholesterolemia and LDL-cholesterol ≥ 100 mg/dL

Title: A Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed Dose/Dose Regimen, Multicenter Study Evaluating the Efficacy and Safety of SAR236553 When Co-administered With 80 mg of Atorvastatin Over 8 Weeks in Patients With Primary Hypercholesterolemia and LDL-cholesterol ≥ 100 mg/dL (≥2.59 mmol/L) on Atorvastatin 10 mg Study Start Date : January 2011 Actual Primary Completion Date : September 2011 Actual Study Completion Date : September 2011 Resource links provided by the National (...) Evaluation of Alirocumab (SAR236553/REGN727) When Co-administered With Atorvastatin in Patients With Primary Hypercholesterolemia and LDL-cholesterol ≥ 100 mg/dL Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) When Co-administered With High Dose of Atorvastatin in Patients With Primary Hypercholesterolemia - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x

2011 Clinical Trials

290. Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) in Patients With Primary Hypercholesterolemia and LDL-cholesterol on Stable Atorvastatin Therapy

Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) in Patients With Primary Hypercholesterolemia and LDL-cholesterol on Stable Atorvastatin Therapy Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) in Patients With Primary Hypercholesterolemia on Stable Atorvastatin Therapy - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved (...) . ClinicalTrials.gov Identifier: NCT01288443 Recruitment Status : Completed First Posted : February 2, 2011 Results First Posted : September 24, 2015 Last Update Posted : September 24, 2015 Sponsor: Sanofi Collaborator: Regeneron Pharmaceuticals Information provided by (Responsible Party): Sanofi Study Details Study Description Go to Brief Summary: Primary Objective: To evaluate the effect of alirocumab (SAR236553/REGN727) on low-density lipoprotein cholesterol (LDL-C) levels after 12 weeks of treatment

2011 Clinical Trials

291. Assessment of the Efficacy of Plant Stanol Esters in Reducing Cholesterol, Medellin 2011

to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 40 participants Allocation: Randomized Intervention Model: Crossover Assignment Masking: Double (Participant, Investigator) Primary Purpose: Treatment Official Title: Assessment of the Efficacy of Plant Stanol Esters in Reducing Cholesterol, Medellin 2011 Study Start Date : October 2011 Estimated Primary Completion Date : December 2011 Estimated Study Completion Date : March 2012 Resource links (...) lactic culture to obtain the optimal characteristics of texture and acidity. With the addition of fruit pulp and supplemented with plant stanol esters (Benecol ®) to help reduce the risk of cardiovascular disease (31). According to Weiss et al, drinkable yogurt with Benecol ® reduces total cholesterol by 5.8% and 9.8% in LDL cholesterol (32). Dietary Supplement: assessment of efficacy of Benecol yogurt Benecol Yogurt and Yogurt placebo for 4 weeks each, at a dose of 100 ml (200 ml in total) of yogurt

2011 Clinical Trials

292. The Effect of Testosterone Replacement on the High Density Lipoprotein Cholesterol Subgroups

cholesterol was measured by calculating the difference between total HDL and the HDL3 subclass. Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility (...) The Effect of Testosterone Replacement on the High Density Lipoprotein Cholesterol Subgroups The Effect of Testosterone Replacement on the High Density Lipoprotein Cholesterol Subgroups - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more

2011 Clinical Trials

293. Efficacy of Prednisone in Patients With Severe Systemic Atheroembolism (Cholesterol Cristal Embolism)

Assignment Masking: Double (Participant, Investigator) Primary Purpose: Treatment Official Title: Efficacy of Prednisone in Patients With Severe Systemic Atheroembolism (Cholesterol Cristal Embolism) Study Start Date : June 2011 Actual Primary Completion Date : September 2015 Actual Study Completion Date : December 2015 Resource links provided by the National Library of Medicine related topics: available for: Arms and Interventions Go to Arm Intervention/treatment Experimental: prednisone • Patients (...) Efficacy of Prednisone in Patients With Severe Systemic Atheroembolism (Cholesterol Cristal Embolism) Efficacy of Prednisone in Patients With Severe Systemic Atheroembolism (Cholesterol Cristal Embolism) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please

2011 Clinical Trials

294. SLOS: The Effect of Simvastatin in Patients Receiving Cholesterol Supplementation

Receiving Cholesterol Supplementation Study Start Date : September 2011 Estimated Primary Completion Date : October 2014 Estimated Study Completion Date : October 2014 Resource links provided by the National Library of Medicine related topics: related topics: available for: resources: Arms and Interventions Go to Arm Intervention/treatment Experimental: Simvastatin Drug: Simvastatin Simvastatin will be administered as a powder mixed with lactose at the dose of 0.5mg/kg/day Placebo Comparator: Placebo (...) is currently receiving cholesterol supplementation Exclusion Criteria: Subjects too ill to travel to the study site Subjects who are unable to safely undergo study procedures Pregnant women Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01434745 Contacts

2011 Clinical Trials

295. Endothelial Function, Lipoproteins, and Inflammation With Low HDL Cholesterol in HIV: ER Niacin Versus Fenofibrate

Endothelial Function, Lipoproteins, and Inflammation With Low HDL Cholesterol in HIV: ER Niacin Versus Fenofibrate Endothelial Function, Lipoproteins, and Inflammation With Low HDL Cholesterol in HIV: ER Niacin Versus Fenofibrate - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number (...) of saved studies (100). Please remove one or more studies before adding more. Endothelial Function, Lipoproteins, and Inflammation With Low HDL Cholesterol in HIV: ER Niacin Versus Fenofibrate The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01426438 Recruitment Status : Completed First Posted : August

2011 Clinical Trials

296. A Study of LY3015014 in Healthy Participants With Elevated Low Density Lipoprotein Cholesterol

A Study of LY3015014 in Healthy Participants With Elevated Low Density Lipoprotein Cholesterol A Study of LY3015014 in Healthy Participants With Elevated Low Density Lipoprotein Cholesterol - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one (...) or more studies before adding more. A Study of LY3015014 in Healthy Participants With Elevated Low Density Lipoprotein Cholesterol The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01426412 Recruitment Status : Completed First Posted : August 31, 2011 Results First Posted : April 5, 2019 Last Update

2011 Clinical Trials

297. Trial to Evaluate Safety and Tolerability of ALN-PCS02 in Subjects With Elevated LDL-Cholesterol (LDL-C)

Trial to Evaluate Safety and Tolerability of ALN-PCS02 in Subjects With Elevated LDL-Cholesterol (LDL-C) Trial to Evaluate Safety and Tolerability of ALN-PCS02 in Subjects With Elevated LDL-Cholesterol (LDL-C) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100 (...) ). Please remove one or more studies before adding more. Trial to Evaluate Safety and Tolerability of ALN-PCS02 in Subjects With Elevated LDL-Cholesterol (LDL-C) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01437059 Recruitment Status : Completed First Posted : September 20, 2011 Last Update Posted

2011 Clinical Trials

298. Effect of Ezetimibe Treatment on Low-density Lipoprotein Cholesterol (LDL-C) Levels in Participants With Coronary Heart Disease (CHD) Already Treated With a Statin (MK-0653A-205 AM1)

/treatment Hypercholesterolemia Drug: Ezetimibe Study Design Go to Layout table for study information Study Type : Observational Actual Enrollment : 1682 participants Observational Model: Cohort Time Perspective: Prospective Official Title: Austrian Cholesterol Screening And Treatment II (ACT II) Study Start Date : May 2009 Actual Primary Completion Date : December 2010 Actual Study Completion Date : December 2010 Resource links provided by the National Library of Medicine related topics: available (...) Effect of Ezetimibe Treatment on Low-density Lipoprotein Cholesterol (LDL-C) Levels in Participants With Coronary Heart Disease (CHD) Already Treated With a Statin (MK-0653A-205 AM1) Effect of Ezetimibe Treatment on Low-density Lipoprotein Cholesterol (LDL-C) Levels in Participants With Coronary Heart Disease (CHD) Already Treated With a Statin (MK-0653A-205 AM1) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration

2011 Clinical Trials

299. Dose Effect of Limicol on (LDL)-Cholesterol Levels

Assignment Masking: Triple (Participant, Care Provider, Investigator) Primary Purpose: Treatment Official Title: Dose Effect of Limicol on (LDL)-Cholesterol Levels in Moderate Hypercholesterolaemia Study Start Date : April 2011 Actual Primary Completion Date : December 2011 Actual Study Completion Date : January 2012 Resource links provided by the National Library of Medicine related topics: Arms and Interventions Go to Arm Intervention/treatment Experimental: Limicol simple dose Dietary Supplement (...) Dose Effect of Limicol on (LDL)-Cholesterol Levels Dose Effect of Limicol on (LDL)-Cholesterol Levels - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Dose Effect of Limicol on (LDL)-Cholesterol Levels

2011 Clinical Trials

300. Effects of Limicol on LDL-cholesterol

Intervention Model: Parallel Assignment Masking: Triple (Participant, Care Provider, Investigator) Primary Purpose: Treatment Official Title: Study of the Effects of Limicol (a Food Supplement) on LDL-cholesterol in Moderate Hypercholesterolemia Subjects Study Start Date : December 2008 Actual Primary Completion Date : May 2011 Actual Study Completion Date : May 2011 Resource links provided by the National Library of Medicine related topics: Arms and Interventions Go to Arm Intervention/treatment (...) Effects of Limicol on LDL-cholesterol Effects of Limicol on LDL-cholesterol - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Effects of Limicol on LDL-cholesterol The safety and scientific validity

2011 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>